VRTX Valuation

Vertex Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

469.650

-2.62(-0.555%)1D

Overview
Forecast
Valuation
Earnings

VRTX Relative Valuation

VRTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VRTX is overvalued; if below, it's undervalued.

Historical Valuation

Vertex Pharmaceuticals Inc (VRTX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 9.95 is considered Overvalued compared with the five-year average of 186.72. The fair price of Vertex Pharmaceuticals Inc (VRTX) is between 322.42 to 440.50 according to relative valuation methord. Compared to the current price of 472.27 USD , Vertex Pharmaceuticals Inc is Overvalued By 7.21%.

Relative Value

Fair Zone

322.42-440.50

Current Price：472.27

7.21%

Overvalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

7.31

P/B

Median3y

6.55

Median5y

6.50

-1.03

FCF Yield

Median3y

2.50

Median5y

3.25

Competitors Valuation Multiple

The average P/S ratio for VRTX's competitors is 2.89, providing a benchmark for relative valuation. Vertex Pharmaceuticals Inc Corp (VRTX) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 2.96%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

VRTX.O

Vertex Pharmaceuticals Inc

Loss

Average P/S: 2.89

2.96%